Connection

Thomas Keane to Humans

This is a "connection" page, showing publications Thomas Keane has written about Humans.
Connection Strength

0.475
  1. Approach to Androgen Deprivation in the Prostate Cancer Patient with Pre-existing Cardiovascular Disease. Curr Urol Rep. 2017 Jun; 18(6):41.
    View in: PubMed
    Score: 0.022
  2. Improved performance of SPECT-CT In-111 capromab pendetide by correlation with diffusion-weighted magnetic resonance imaging for identifying metastatic pelvic lymphadenopathy in prostate cancer. World J Urol. 2013 Dec; 31(6):1327-32.
    View in: PubMed
    Score: 0.016
  3. Androgen deprivation therapy: past, present and future. BJU Int. 2012 Jun; 109 Suppl 6:1-12.
    View in: PubMed
    Score: 0.015
  4. Capromab pendetide scanning has a potential role in optimizing patient selection for salvage cryosurgical ablation of the prostate. Urology. 2010 Nov; 76(5):1162-7.
    View in: PubMed
    Score: 0.014
  5. The multi-disciplinary management of high-risk prostate cancer. Urol Oncol. 2012 Jan-Feb; 30(1):3-15.
    View in: PubMed
    Score: 0.013
  6. Evaluation of modern pathological criteria for positive margins in radical prostatectomy specimens and their use for predicting biochemical recurrence. BJU Int. 2009 Feb; 103(3):327-31.
    View in: PubMed
    Score: 0.012
  7. Perineal prostatectomy in the age of minimally invasive surgery. J Ark Med Soc. 2008 Sep; 105(3):67-8.
    View in: PubMed
    Score: 0.012
  8. Serum testosterone recovery after cessation of long-term luteinizing hormone-releasing hormone agonist in patients with prostate cancer. Urology. 2008 Jun; 71(6):1177-80.
    View in: PubMed
    Score: 0.011
  9. Pathologically confirmed port site metastasis after laparoscopic radical prostatectomy: case report and literature review. Urology. 2007 Dec; 70(6):1222.e9-11.
    View in: PubMed
    Score: 0.011
  10. Salvage options for biochemical recurrence after primary therapy for prostate cancer. Can J Urol. 2007 Dec; 14 Suppl 1:2-9.
    View in: PubMed
    Score: 0.011
  11. Salvage cryosurgical ablation of the prostate for local recurrence after radiation therapy: improved outcomes utilizing a capromab pendetide scan and biopsy algorithm. Can J Urol. 2007 Dec; 14 Suppl 1:24-7.
    View in: PubMed
    Score: 0.011
  12. Abnormal fluorescence in situ hybridization analysis in collecting duct carcinoma. Urology. 2005 Nov; 66(5):1110.
    View in: PubMed
    Score: 0.010
  13. Partial segmental thrombosis of corpus cavernosum: case report and review of world literature. Urology. 2005 Jul; 66(1):194.
    View in: PubMed
    Score: 0.010
  14. Bladder cancer--resection/ablation. Surg Oncol Clin N Am. 2005 Apr; 14(2):321-52.
    View in: PubMed
    Score: 0.009
  15. Community-acquired methicillin-resistant Staphylococcus aureus prostatic abscess. Urology. 2004 Oct; 64(4):808-10.
    View in: PubMed
    Score: 0.009
  16. Tissue disposition of 5-o-carboranyluracil--a novel agent for the boron neutron capture therapy of prostate cancer. Nucleosides Nucleotides Nucleic Acids. 2004; 23(1-2):291-306.
    View in: PubMed
    Score: 0.009
  17. PC-SPES withdrawal response. Acta Oncol. 2004; 43(8):772-3.
    View in: PubMed
    Score: 0.009
  18. Impact of Late Dosing on Testosterone Suppression with 2 Different Leuprolide Acetate Formulations: In Situ Gel and Microsphere. An Analysis of United States Clinical Data. J Urol. 2021 02; 205(2):554-560.
    View in: PubMed
    Score: 0.007
  19. Evolving understanding and categorization of prostate cancer: preventing progression to metastatic castration-resistant prostate cancer: RADAR IV. Can J Urol. 2020 10; 27(5):10352-10362.
    View in: PubMed
    Score: 0.007
  20. Comparison of Urologist- vs Gastroenterologist-Directed Extracorporeal Shock Wave Lithotripsy for Pancreaticolithiasis. Clin Gastroenterol Hepatol. 2021 06; 19(6):1234-1239.
    View in: PubMed
    Score: 0.007
  21. Mapping and Analysis of US State and Urban Local Sodium Reduction Laws. J Public Health Manag Pract. 2020 Mar/Apr; 26 Suppl 2, Advancing Legal Epidemiology:S62-S70.
    View in: PubMed
    Score: 0.007
  22. Embryology, anatomy, and surgical applications of the kidney and ureter. Surg Clin North Am. 2000 Feb; 80(1):381-401, xiv.
    View in: PubMed
    Score: 0.007
  23. The Impact of Late Luteinizing Hormone-Releasing Hormone Agonist Dosing on Testosterone Suppression in Patients with Prostate Cancer: An Analysis of United States Clinical Data. J Urol. 2020 Apr; 203(4):743-750.
    View in: PubMed
    Score: 0.006
  24. A Clinician's Guide to Next Generation Imaging in Patients With Advanced Prostate Cancer (RADAR III). J Urol. 2019 04; 201(4):682-692.
    View in: PubMed
    Score: 0.006
  25. FSH suppression and tumour control in patients with prostate cancer during androgen deprivation with a GnRH agonist or antagonist. Scand J Urol. 2018 Oct - Dec; 52(5-6):349-357.
    View in: PubMed
    Score: 0.006
  26. Camptothecin analogues/cisplatin: an effective treatment of advanced bladder cancer in a preclinical in vivo model system. J Urol. 1998 Jul; 160(1):252-6.
    View in: PubMed
    Score: 0.006
  27. Identification of men with low-risk biopsy-confirmed prostate cancer as candidates for active surveillance. Urol Oncol. 2018 06; 36(6):310.e7-310.e13.
    View in: PubMed
    Score: 0.006
  28. The potential role of follicle-stimulating hormone in the cardiovascular, metabolic, skeletal, and cognitive effects associated with androgen deprivation therapy. Urol Oncol. 2017 05; 35(5):183-191.
    View in: PubMed
    Score: 0.005
  29. The Role of Therapeutic Layering in Optimizing Treatment for Patients With Castration-resistant Prostate Cancer (Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence II). Urology. 2017 Jun; 104:150-159.
    View in: PubMed
    Score: 0.005
  30. The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-na?ve Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2016 10; 70(4):675-683.
    View in: PubMed
    Score: 0.005
  31. Six Weeks of Fluoroquinolone Antibiotic Therapy for Patients With Elevated Serum Prostate-specific Antigen Is Not Clinically Beneficial: A Randomized Controlled Clinical Trial. Urology. 2016 Apr; 90:32-7.
    View in: PubMed
    Score: 0.005
  32. Conservative renal surgery. Has it a role in renal cell carcinoma? Surg Oncol Clin N Am. 1995 Apr; 4(2):295-306.
    View in: PubMed
    Score: 0.005
  33. Avoiding obsolescence in advanced prostate cancer management: a guide for urologists. BJU Int. 2015 Feb; 115(2):188-97.
    View in: PubMed
    Score: 0.005
  34. Methoxypsoralen phototherapy of transitional cell carcinoma. Urology. 1994 Dec; 44(6):842-6.
    View in: PubMed
    Score: 0.005
  35. Selective estrogen receptor alpha agonist GTx-758 decreases testosterone with reduced side effects of androgen deprivation therapy in men with advanced prostate cancer. Eur Urol. 2015 Feb; 67(2):334-41.
    View in: PubMed
    Score: 0.004
  36. A phase II study of gemcitabine and irinotecan in patients with locally advanced or metastatic bladder cancer. Am J Clin Oncol. 2014 Apr; 37(2):188-93.
    View in: PubMed
    Score: 0.004
  37. Combination versus single agent therapy in effecting complete therapeutic response in human bladder cancer: analysis of cisplatin and/or 5-fluorouracil in an in vivo survival model. Cancer Res. 1994 Jan 15; 54(2):475-81.
    View in: PubMed
    Score: 0.004
  38. Challenges and recommendations for early identification of metastatic disease in prostate cancer. Urology. 2014 Mar; 83(3):664-9.
    View in: PubMed
    Score: 0.004
  39. Phase I trial of weekly docetaxel, total androgen blockade, and image-guided intensity-modulated radiotherapy for localized high-risk prostate adenocarcinoma. Clin Genitourin Cancer. 2014 Apr; 12(2):80-6.
    View in: PubMed
    Score: 0.004
  40. Impact of prostate cancer on sexual relationships: a longitudinal perspective on intimate partners' experiences. J Sex Med. 2013 Dec; 10(12):3135-43.
    View in: PubMed
    Score: 0.004
  41. Radiation-induced acid ceramidase confers prostate cancer resistance and tumor relapse. J Clin Invest. 2013 Oct; 123(10):4344-58.
    View in: PubMed
    Score: 0.004
  42. Burden among partner caregivers of patients diagnosed with localized prostate cancer within 1?year after diagnosis: an economic perspective. Support Care Cancer. 2013 Dec; 21(12):3461-9.
    View in: PubMed
    Score: 0.004
  43. Editorial comment. Urology. 2012 Sep; 80(3):563.
    View in: PubMed
    Score: 0.004
  44. Willingness to pay for prostate cancer treatment among patients and their family members at 1 year after diagnosis. Value Health. 2012 Jul-Aug; 15(5):716-23.
    View in: PubMed
    Score: 0.004
  45. Editorial comment. Urology. 2012 Jul; 80(1):168.
    View in: PubMed
    Score: 0.004
  46. Vitamin D3 supplementation at 4000 international units per day for one year results in a decrease of positive cores at repeat biopsy in subjects with low-risk prostate cancer under active surveillance. J Clin Endocrinol Metab. 2012 Jul; 97(7):2315-24.
    View in: PubMed
    Score: 0.004
  47. The therapeutic impact of dipyridamole: chemopotentiation of the cytotoxic combination 5-fluorouracil/cisplatin in an animal model of human bladder cancer. J Urol. 1991 Nov; 146(5):1418-24.
    View in: PubMed
    Score: 0.004
  48. Contemporary diagnosis and management of squamous cell carcinoma (SCC) of the penis. BJU Int. 2011 Nov; 108(9):1378-92.
    View in: PubMed
    Score: 0.004
  49. Diagnostic performance of In-111 capromab pendetide SPECT/CT in localized and metastatic prostate cancer. Clin Nucl Med. 2011 Oct; 36(10):872-8.
    View in: PubMed
    Score: 0.004
  50. Detection of mitochondrial deoxyribonucleic acid alterations in urine from urothelial cell carcinoma patients. Int J Cancer. 2012 Jul 01; 131(1):158-64.
    View in: PubMed
    Score: 0.004
  51. Penile cancer: an analysis of socioeconomic factors at a southeastern tertiary referral center. Can J Urol. 2011 Feb; 18(1):5524-8.
    View in: PubMed
    Score: 0.004
  52. Provider and partner interactions in the treatment decision-making process for newly diagnosed localized prostate cancer. BJU Int. 2011 Sep; 108(6):851-6; discussion 856-7.
    View in: PubMed
    Score: 0.004
  53. A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol. 2011 Apr; 59(4):543-52.
    View in: PubMed
    Score: 0.003
  54. Autophagy is increased in prostate cancer cells overexpressing acid ceramidase and enhances resistance to C6 ceramide. Prostate Cancer Prostatic Dis. 2011 Mar; 14(1):30-7.
    View in: PubMed
    Score: 0.003
  55. Patient preferences and urologist recommendations among local-stage prostate cancer patients who present for initial consultation and second opinions. World J Urol. 2011 Feb; 29(1):3-9.
    View in: PubMed
    Score: 0.003
  56. Dipyridamole-cisplatin potentiation: enhanced in vivo cytotoxicity in xenograft models of human testicular and bladder cancers. J Urol. 1990 Oct; 144(4):1004-9.
    View in: PubMed
    Score: 0.003
  57. Chronic calcific pancreatitis: combination ERCP and extracorporeal shock wave lithotripsy for pancreatic duct stones. South Med J. 2010 Jun; 103(6):505-8.
    View in: PubMed
    Score: 0.003
  58. Preliminary treatment considerations among men with newly diagnosed prostate cancer. Am J Manag Care. 2010 May 01; 16(5):e121-30.
    View in: PubMed
    Score: 0.003
  59. Acid ceramidase upregulation in prostate cancer: role in tumor development and implications for therapy. Expert Opin Ther Targets. 2009 Dec; 13(12):1449-58.
    View in: PubMed
    Score: 0.003
  60. Acid ceramidase upregulation in prostate cancer cells confers resistance to radiation: AC inhibition, a potential radiosensitizer. Mol Ther. 2009 Mar; 17(3):430-8.
    View in: PubMed
    Score: 0.003
  61. Assessing the gene space in draft genomes. Nucleic Acids Res. 2009 Jan; 37(1):289-97.
    View in: PubMed
    Score: 0.003
  62. Upregulated expression of complement inhibitory proteins on bladder cancer cells and anti-MUC1 antibody immune selection. Int J Cancer. 2008 Sep 15; 123(6):1357-63.
    View in: PubMed
    Score: 0.003
  63. Acid ceramidase inhibition: a novel target for cancer therapy. Front Biosci. 2008 Jan 01; 13:2293-8.
    View in: PubMed
    Score: 0.003
  64. Managing prostate cancer: the role of hormone therapy. Can J Urol. 2007 Dec; 14 Suppl 1:10-8.
    View in: PubMed
    Score: 0.003
  65. Five year results of a randomized trial comparing hyperfractionated to conventional radiotherapy over four weeks in locally advanced head and neck cancer. Radiother Oncol. 2007 Oct; 85(1):7-16.
    View in: PubMed
    Score: 0.003
  66. Functional analysis of the host defense peptide Human Beta Defensin-1: new insight into its potential role in cancer. Mol Immunol. 2008 Feb; 45(3):839-48.
    View in: PubMed
    Score: 0.003
  67. Adjuvant androgen deprivation therapy augments cure and long-term cancer control in men with poor prognosis, nonmetastatic prostate cancer. Prostate Cancer Prostatic Dis. 2008; 11(1):46-52.
    View in: PubMed
    Score: 0.003
  68. Inferior vena cava reconstruction using fresh inferior vena cava allograft following caval resection for leiomyosarcoma: midterm results. J Vasc Surg. 2007 Jul; 46(1):140-3.
    View in: PubMed
    Score: 0.003
  69. The functional effects of acid ceramidase overexpression in prostate cancer progression and resistance to chemotherapy. Cancer Biol Ther. 2007 Sep; 6(9):1455-60.
    View in: PubMed
    Score: 0.003
  70. A prospective randomized EORTC intergroup phase 3 study comparing the complications of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol. 2007 Jun; 51(6):1606-15.
    View in: PubMed
    Score: 0.003
  71. Involvement of sphingolipids in apoptin-induced cell killing. Mol Ther. 2006 Nov; 14(5):627-36.
    View in: PubMed
    Score: 0.003
  72. Modulation of ceramide metabolism enhances viral protein apoptin's cytotoxicity in prostate cancer. Mol Ther. 2006 Nov; 14(5):637-46.
    View in: PubMed
    Score: 0.003
  73. Prostate cancer disparities in South Carolina: early detection, special programs, and descriptive epidemiology. J S C Med Assoc. 2006 Aug; 102(7):241-9.
    View in: PubMed
    Score: 0.003
  74. Evaluation of survivin reverse transcriptase-polymerase chain reaction for noninvasive detection of bladder cancer. J Urol. 2006 Jun; 175(6):2312-6.
    View in: PubMed
    Score: 0.003
  75. Fluorescence in situ hybridization for detecting transitional cell carcinoma: implications for clinical practice. BJU Int. 2005 Dec; 96(9):1280-5.
    View in: PubMed
    Score: 0.002
  76. [Reevaluation of MAB therapy and progress of endocrine therapy]. Gan To Kagaku Ryoho. 2005 May; 32(5):705-28.
    View in: PubMed
    Score: 0.002
  77. The present and future for gene and viral therapy of directly accessible prostate and squamous cell cancers of the head and neck. Future Oncol. 2005 Feb; 1(1):115-23.
    View in: PubMed
    Score: 0.002
  78. Experience with coapted gastric tube outlet and composite gastrointestinal reservoir for continent cutaneous urinary diversion. J Urol. 2004 Jan; 171(1):229-31.
    View in: PubMed
    Score: 0.002
  79. Concomitant intraoperative renal artery embolization and resection of complex renal carcinoma. J Vasc Surg. 2003 Sep; 38(3):446-50.
    View in: PubMed
    Score: 0.002
  80. Camptothecin analogues and vinblastine in the treatment of renal cell carcinoma: an in vivo study using a human orthotopic renal cancer xenograft. Urol Oncol. 2003 Jan-Feb; 21(1):49-57.
    View in: PubMed
    Score: 0.002
  81. Critical evaluation of hormonal therapy for carcinoma of the prostate. Urology. 2002 Aug; 60(2):201-8.
    View in: PubMed
    Score: 0.002
  82. Diuretic renogram in a patient with a urinary diversion: avoiding a false-positive diagnosis of obstruction with an indwelling catheter. Clin Nucl Med. 2001 Jul; 26(7):631-2.
    View in: PubMed
    Score: 0.002
  83. Gunshot wounds to the ureter: a 40-year experience at Grady Memorial Hospital. J Urol. 2001 Jul; 166(1):119-21.
    View in: PubMed
    Score: 0.002
  84. Relationship of cytokeratin 20 and CD44 protein expression with WHO/ISUP grade in pTa and pT1 papillary urothelial neoplasia. Mod Pathol. 2000 Dec; 13(12):1315-23.
    View in: PubMed
    Score: 0.002
  85. Poor prognosis associated with thrombocytosis in patients with renal cell carcinoma. BJU Int. 2000 Aug; 86(3):203-7.
    View in: PubMed
    Score: 0.002
  86. pT1 urothelial carcinoma of the bladder: criteria for diagnosis, pitfalls, and clinical implications. Adv Anat Pathol. 2000 Jan; 7(1):13-25.
    View in: PubMed
    Score: 0.002
  87. Evaluation of staging lymphadenectomy in prostate cancer. Urology. 1998 Oct; 52(4):663-7.
    View in: PubMed
    Score: 0.001
  88. Two cases of vasculitis of the urinary bladder: diagnostic and pathogenetic considerations. Arch Pathol Lab Med. 1998 Oct; 122(10):903-6.
    View in: PubMed
    Score: 0.001
  89. Enhanced control by radiotherapy of cervical lymph node metastases arising from nasopharyngeal carcinoma compared with nodal metastases from other head and neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys. 1997 Aug 01; 39(1):149-54.
    View in: PubMed
    Score: 0.001
  90. Normal range prostate-specific antigen versus age-specific prostate-specific antigen in screening prostate adenocarcinoma. Urology. 1995 Aug; 46(2):200-4.
    View in: PubMed
    Score: 0.001
  91. Outcome following radiotherapy in verrucous carcinoma of the larynx. Int J Radiat Oncol Biol Phys. 1995 Jun 15; 32(3):611-7.
    View in: PubMed
    Score: 0.001
  92. Gastric cancer: the case for a more selective policy in surgical management. J R Coll Surg Edinb. 1993 Aug; 38(4):208-12.
    View in: PubMed
    Score: 0.001
  93. Use of protective plastic sheath for prostatic biopsy. Urology. 1992 Jan; 39(1):88-9.
    View in: PubMed
    Score: 0.001
  94. Characterization of a new model of human prostatic cancer: the multicellular tumor spheroid. Int J Cancer. 1990 Aug 15; 46(2):238-44.
    View in: PubMed
    Score: 0.001
  95. Enhanced in vivo cytotoxicity of recombinant human tumor necrosis factor with etoposide in human renal cell carcinoma. Evaluation in a pre-clinical model. Urol Res. 1990; 18(4):245-50.
    View in: PubMed
    Score: 0.001
  96. Prostate-specific antigen. Superior serum marker for prostatic carcinoma. Ir J Med Sci. 1987 May; 156(5):138-41.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.